| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Meningococcal Infections | 5 | 2019 | 216 | 1.58 | Why? |
| DiGeorge Syndrome | 2 | 2019 | 15 | 0.93 | Why? |
| Meningococcal Vaccines | 3 | 2018 | 225 | 0.85 | Why? |
| Puberty, Precocious | 1 | 2020 | 33 | 0.85 | Why? |
| Puberty | 1 | 2020 | 53 | 0.85 | Why? |
| Streptococcus pneumoniae | 3 | 2019 | 827 | 0.75 | Why? |
| Neisseria meningitidis, Serogroup B | 1 | 2018 | 66 | 0.73 | Why? |
| Pneumococcal Vaccines | 3 | 2019 | 571 | 0.73 | Why? |
| Nasal Cavity | 2 | 2021 | 909 | 0.72 | Why? |
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2017 | 46 | 0.71 | Why? |
| Leukocyte Common Antigens | 1 | 2017 | 101 | 0.70 | Why? |
| Neonatal Screening | 2 | 2019 | 285 | 0.70 | Why? |
| Neisseria meningitidis | 2 | 2018 | 229 | 0.68 | Why? |
| Arthritis, Infectious | 1 | 2018 | 111 | 0.67 | Why? |
| Immunologic Deficiency Syndromes | 3 | 2018 | 368 | 0.67 | Why? |
| Vaccines, Conjugate | 1 | 2019 | 328 | 0.64 | Why? |
| Genetic Association Studies | 1 | 2019 | 559 | 0.62 | Why? |
| Pneumonia, Pneumococcal | 1 | 2019 | 251 | 0.61 | Why? |
| Neoplasm Proteins | 1 | 2019 | 501 | 0.53 | Why? |
| Serogroup | 5 | 2019 | 510 | 0.53 | Why? |
| Pleural Effusion | 1 | 2019 | 680 | 0.49 | Why? |
| Pneumococcal Infections | 3 | 2017 | 562 | 0.49 | Why? |
| Oropharynx | 2 | 2020 | 1581 | 0.48 | Why? |
| Vaccination Coverage | 1 | 2020 | 1249 | 0.44 | Why? |
| Immunization Programs | 3 | 2020 | 2006 | 0.41 | Why? |
| Autoimmunity | 1 | 2017 | 841 | 0.41 | Why? |
| Neisseria meningitidis, Serogroup C | 2 | 2019 | 46 | 0.37 | Why? |
| Bacteriological Techniques | 1 | 2011 | 239 | 0.37 | Why? |
| DNA, Bacterial | 2 | 2017 | 835 | 0.35 | Why? |
| Severe Combined Immunodeficiency | 2 | 2019 | 107 | 0.35 | Why? |
| Poliovirus Vaccine, Inactivated | 2 | 2018 | 72 | 0.34 | Why? |
| Genetic Predisposition to Disease | 4 | 2019 | 4027 | 0.34 | Why? |
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2018 | 92 | 0.34 | Why? |
| Adenosine Deaminase | 2 | 2018 | 85 | 0.33 | Why? |
| Specimen Handling | 2 | 2021 | 6190 | 0.31 | Why? |
| B-Lymphocytes | 2 | 2019 | 4418 | 0.30 | Why? |
| Hepatitis B Vaccines | 2 | 2018 | 245 | 0.30 | Why? |
| Child | 24 | 2021 | 70012 | 0.30 | Why? |
| Carrier State | 3 | 2019 | 2100 | 0.29 | Why? |
| Italy | 18 | 2021 | 38444 | 0.25 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.24 | Why? |
| Child, Preschool | 19 | 2021 | 36283 | 0.24 | Why? |
| Drug Hypersensitivity | 2 | 2019 | 401 | 0.23 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 2 | 2019 | 72 | 0.22 | Why? |
| Infant, Newborn | 8 | 2020 | 23105 | 0.21 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.21 | Why? |
| Receptors, Adrenergic, beta-3 | 1 | 2019 | 10 | 0.20 | Why? |
| Infant | 13 | 2021 | 30274 | 0.19 | Why? |
| Melanoma, Experimental | 1 | 2019 | 57 | 0.19 | Why? |
| Nasal Mucosa | 2 | 2021 | 1218 | 0.19 | Why? |
| Genetic Testing | 2 | 2019 | 395 | 0.19 | Why? |
| Empyema, Pleural | 1 | 2019 | 46 | 0.19 | Why? |
| Immunocompromised Host | 3 | 2022 | 5150 | 0.18 | Why? |
| Haemophilus influenzae type b | 1 | 2017 | 30 | 0.18 | Why? |
| Thyroiditis, Autoimmune | 1 | 2018 | 86 | 0.18 | Why? |
| Bisexuality | 1 | 2018 | 119 | 0.17 | Why? |
| Haemophilus Vaccines | 1 | 2017 | 76 | 0.17 | Why? |
| Immunophenotyping | 2 | 2019 | 1290 | 0.17 | Why? |
| Haemophilus Infections | 1 | 2017 | 69 | 0.17 | Why? |
| Mycobacterium avium-intracellulare Infection | 1 | 2017 | 59 | 0.17 | Why? |
| Polymerase Chain Reaction | 2 | 2019 | 6740 | 0.17 | Why? |
| Thymus Gland | 1 | 2017 | 126 | 0.17 | Why? |
| Whole Exome Sequencing | 1 | 2019 | 437 | 0.17 | Why? |
| Meningitis, Meningococcal | 1 | 2018 | 114 | 0.16 | Why? |
| Tertiary Healthcare | 1 | 2021 | 616 | 0.16 | Why? |
| Incidence | 7 | 2021 | 25622 | 0.16 | Why? |
| Bacterial Vaccines | 1 | 2018 | 139 | 0.16 | Why? |
| Ceftriaxone | 1 | 2019 | 365 | 0.16 | Why? |
| Basophils | 1 | 2017 | 179 | 0.16 | Why? |
| Amoxicillin | 1 | 2017 | 98 | 0.16 | Why? |
| Adolescent | 17 | 2020 | 86841 | 0.16 | Why? |
| Bordetella pertussis | 1 | 2017 | 117 | 0.16 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 245 | 0.16 | Why? |
| Hospitals, District | 1 | 2017 | 136 | 0.15 | Why? |
| Osteomyelitis | 1 | 2017 | 131 | 0.15 | Why? |
| Agammaglobulinemia | 1 | 2018 | 213 | 0.15 | Why? |
| Hypothyroidism | 1 | 2018 | 239 | 0.15 | Why? |
| Hypersensitivity, Immediate | 1 | 2017 | 134 | 0.15 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2020 | 11367 | 0.14 | Why? |
| Immune Tolerance | 1 | 2020 | 608 | 0.14 | Why? |
| Whooping Cough | 1 | 2017 | 201 | 0.14 | Why? |
| Humans | 43 | 2022 | 930598 | 0.14 | Why? |
| Dried Blood Spot Testing | 1 | 2017 | 383 | 0.13 | Why? |
| Arthritis | 1 | 2017 | 288 | 0.13 | Why? |
| Skin Tests | 3 | 2017 | 229 | 0.13 | Why? |
| Polyethylene Glycols | 1 | 2018 | 574 | 0.13 | Why? |
| Leukemia, Myeloid, Acute | 1 | 2020 | 676 | 0.13 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.13 | Why? |
| Hospitals, Pediatric | 2 | 2021 | 1792 | 0.12 | Why? |
| Adenosine | 1 | 2017 | 509 | 0.12 | Why? |
| Homosexuality, Male | 2 | 2019 | 1158 | 0.12 | Why? |
| Male | 28 | 2021 | 367725 | 0.12 | Why? |
| Food Hypersensitivity | 1 | 2018 | 397 | 0.12 | Why? |
| Female | 26 | 2021 | 380317 | 0.12 | Why? |
| History, 21st Century | 1 | 2019 | 1849 | 0.11 | Why? |
| Ribavirin | 1 | 2018 | 1182 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.10 | Why? |
| Blood | 1 | 2011 | 274 | 0.10 | Why? |
| Interferon-alpha | 1 | 2018 | 1442 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.10 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2017 | 1439 | 0.09 | Why? |
| Immunity, Herd | 1 | 2017 | 1011 | 0.09 | Why? |
| Infarction, Posterior Cerebral Artery | 1 | 2008 | 27 | 0.09 | Why? |
| Rubber | 1 | 2008 | 6 | 0.09 | Why? |
| Hyperhomocysteinemia | 1 | 2008 | 24 | 0.09 | Why? |
| Latex Hypersensitivity | 1 | 2008 | 10 | 0.09 | Why? |
| Forkhead Transcription Factors | 1 | 2010 | 231 | 0.09 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Urine | 1 | 2011 | 469 | 0.09 | Why? |
| Epidemiological Monitoring | 1 | 2021 | 3493 | 0.09 | Why? |
| Heart Septal Defects, Atrial | 1 | 2008 | 61 | 0.09 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.09 | Why? |
| Lung Transplantation | 1 | 2019 | 1554 | 0.09 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2018 | 2093 | 0.09 | Why? |
| Body Mass Index | 1 | 2020 | 4306 | 0.08 | Why? |
| Blood Coagulation Disorders, Inherited | 1 | 2008 | 82 | 0.08 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.08 | Why? |
| Phenotype | 4 | 2019 | 4037 | 0.08 | Why? |
| Parents | 1 | 2021 | 2758 | 0.08 | Why? |
| Lymphopenia | 1 | 2019 | 2669 | 0.08 | Why? |
| Anti-Bacterial Agents | 2 | 2019 | 10083 | 0.08 | Why? |
| Health Personnel | 3 | 2021 | 29646 | 0.08 | Why? |
| Lymphocytes | 1 | 2019 | 3056 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Skin Neoplasms | 1 | 2019 | 1679 | 0.07 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.07 | Why? |
| Autoimmune Diseases | 1 | 2019 | 1996 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.07 | Why? |
| Cohort Studies | 6 | 2019 | 36005 | 0.07 | Why? |
| Cross-Sectional Studies | 3 | 2021 | 53120 | 0.07 | Why? |
| France | 1 | 2021 | 12074 | 0.07 | Why? |
| Community-Acquired Infections | 1 | 2017 | 2328 | 0.07 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.07 | Why? |
| Antineoplastic Agents | 1 | 2020 | 3550 | 0.07 | Why? |
| Young Adult | 7 | 2019 | 93724 | 0.07 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.06 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.06 | Why? |
| Consensus | 1 | 2018 | 6345 | 0.06 | Why? |
| Patient Safety | 1 | 2018 | 4885 | 0.06 | Why? |
| Age of Onset | 2 | 2019 | 557 | 0.06 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.06 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.06 | Why? |
| Fever | 1 | 2018 | 7795 | 0.06 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.06 | Why? |
| Adult | 10 | 2021 | 244371 | 0.05 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.05 | Why? |
| Virus Diseases | 1 | 2018 | 3779 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3832 | 0.05 | Why? |
| Genotype | 3 | 2019 | 4697 | 0.05 | Why? |
| Brain | 1 | 2017 | 5133 | 0.05 | Why? |
| Tumor Cells, Cultured | 1 | 2019 | 254 | 0.05 | Why? |
| Vaccination | 3 | 2019 | 19050 | 0.05 | Why? |
| Coculture Techniques | 1 | 2019 | 258 | 0.05 | Why? |
| Serotyping | 1 | 2018 | 154 | 0.05 | Why? |
| Meningitis, Haemophilus | 1 | 2017 | 12 | 0.05 | Why? |
| HLA-DQ alpha-Chains | 1 | 2017 | 21 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2019 | 264 | 0.04 | Why? |
| Nervous System Diseases | 1 | 2017 | 4092 | 0.04 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2010 | 1645 | 0.04 | Why? |
| Latex | 1 | 1997 | 9 | 0.04 | Why? |
| Vaccines, Combined | 1 | 2017 | 67 | 0.04 | Why? |
| Mycobacterium avium Complex | 1 | 2017 | 61 | 0.04 | Why? |
| Immunoglobulins, Intravenous | 1 | 2010 | 2705 | 0.04 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.04 | Why? |
| Sensitivity and Specificity | 3 | 2017 | 22971 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2010 | 3607 | 0.04 | Why? |
| Viral Vaccines | 1 | 2018 | 7560 | 0.04 | Why? |
| Pertussis Vaccine | 1 | 2017 | 89 | 0.04 | Why? |
| Tanzania | 1 | 2017 | 294 | 0.04 | Why? |
| Thyrotropin | 1 | 2018 | 262 | 0.04 | Why? |
| Behavior, Animal | 1 | 2017 | 136 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2017 | 6817 | 0.04 | Why? |
| Thyroxine | 1 | 2018 | 250 | 0.04 | Why? |
| Genetic Markers | 1 | 2017 | 318 | 0.04 | Why? |
| Mycophenolic Acid | 1 | 2018 | 383 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.04 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.04 | Why? |
| Adrenergic beta-Antagonists | 1 | 2019 | 465 | 0.04 | Why? |
| Immunoglobulin E | 1 | 2019 | 557 | 0.04 | Why? |
| Tacrolimus | 1 | 2018 | 435 | 0.04 | Why? |
| Behavior | 1 | 2017 | 252 | 0.03 | Why? |
| Immunologic Tests | 1 | 2017 | 445 | 0.03 | Why? |
| Syndrome | 1 | 2019 | 1310 | 0.03 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.03 | Why? |
| Cell Survival | 1 | 2019 | 1581 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2019 | 27595 | 0.03 | Why? |
| Chile | 1 | 2017 | 1095 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Infant, Premature | 1 | 2017 | 883 | 0.03 | Why? |
| Aged | 5 | 2020 | 215776 | 0.03 | Why? |
| Cell Proliferation | 1 | 2019 | 1973 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Middle Aged | 5 | 2021 | 270681 | 0.03 | Why? |
| Immunization Schedule | 1 | 2018 | 1305 | 0.03 | Why? |
| Vaccines, Inactivated | 1 | 2018 | 1562 | 0.03 | Why? |
| Drug Industry | 1 | 2018 | 689 | 0.03 | Why? |
| Tissue Donors | 1 | 2019 | 1679 | 0.02 | Why? |
| Immunosuppressive Agents | 2 | 2018 | 6331 | 0.02 | Why? |
| Case-Control Studies | 2 | 2019 | 17671 | 0.02 | Why? |
| Hemianopsia | 1 | 2008 | 5 | 0.02 | Why? |
| Sputum | 1 | 2017 | 1720 | 0.02 | Why? |
| Occipital Lobe | 1 | 2008 | 26 | 0.02 | Why? |
| Sexual and Gender Minorities | 1 | 2019 | 1019 | 0.02 | Why? |
| Communicable Disease Control | 1 | 2018 | 29620 | 0.02 | Why? |
| Mice | 2 | 2019 | 21357 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2019 | 5542 | 0.02 | Why? |
| Cerebral Arteries | 1 | 2008 | 90 | 0.02 | Why? |
| Hypertension, Pulmonary | 1 | 2017 | 970 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Intracranial Embolism | 1 | 2008 | 73 | 0.02 | Why? |
| Prevalence | 3 | 2019 | 25773 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 3633 | 0.02 | Why? |
| Vitamin B 12 | 1 | 2008 | 132 | 0.02 | Why? |
| Folic Acid | 1 | 2008 | 172 | 0.02 | Why? |
| Autoantibodies | 1 | 2018 | 2094 | 0.02 | Why? |
| Hypersensitivity | 1 | 1997 | 1137 | 0.02 | Why? |
| Age Factors | 2 | 2017 | 21039 | 0.02 | Why? |
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 317 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.02 | Why? |
| Antiviral Agents | 1 | 2018 | 41703 | 0.02 | Why? |
| Stroke | 1 | 2008 | 8839 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.02 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2010 | 698 | 0.02 | Why? |
| Risk Assessment | 2 | 2017 | 25439 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2018 | 9537 | 0.02 | Why? |
| Age Distribution | 1 | 2012 | 3567 | 0.02 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Flow Cytometry | 1 | 2010 | 2393 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2019 | 10998 | 0.01 | Why? |
| Sepsis | 1 | 2017 | 3517 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Risk Factors | 2 | 2019 | 71621 | 0.01 | Why? |
| Animals | 2 | 2019 | 78931 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Health Policy | 1 | 2018 | 6242 | 0.01 | Why? |
| Gloves, Surgical | 1 | 1997 | 50 | 0.01 | Why? |
| Acute Disease | 1 | 2010 | 6029 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| RNA, Messenger | 1 | 2010 | 5131 | 0.01 | Why? |
| Population Surveillance | 1 | 2012 | 4967 | 0.01 | Why? |
| Prognosis | 1 | 2017 | 32490 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Outpatient Clinics, Hospital | 1 | 1997 | 523 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 13720 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.01 | Why? |
| Anticoagulants | 1 | 2008 | 9563 | 0.00 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.00 | Why? |
| Hospitals, University | 1 | 1997 | 4173 | 0.00 | Why? |